Sally Ann Forsyth to join SBC
Stevenage Bioscience Catalyst (SBC) has announced that Dr. Sally Ann Forsyth is set to join the company as CEO in March 2018.
Forsyth will be leaving her position as CEO of Norwich Research Park, which she joined in 2013, for SBC.
Stevenage Bioscience Catalyst opened as the UK’s first open innovation biomedical campus in 2012 and is a joint venture between Government, GlaxoSmithKline and Wellcome.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium